Axol Bioscience Ltd

World leaders in iPSC technology supporting the next generation of advanced models for drug discovery We provide biopharma and virtual organizations with human iPSC-derived cells and outsourced laboratory services to support drug discovery in the neurodegenerative, neuroinflammatory, and cardiotoxicity areas. As leaders in human induced pluripotent stem cell (iPSC) products and services, we support the pursuit of more human-relevant in vitro models to develop better, safer therapies. We have over a decade of experience supplying top ten Biopharma institutions and drug discovery companies with robust, high-quality in vitro models and custom lab services. Our industry-leading iPSC capabilities support the pursuit...

Ipsc derived cells,ipsc laboratory services,ipsc reprogramming,ipsc differentiation,ipsc gene editing,ipsc derived neurons,ipsc derived microglia,and ipsc cardiomyocytes

Axol bioscience ltd operates in the Biotechnology research industry.

Axol bioscience ltd's revenue is 11m - 100m

Axol bioscience ltd has 11 - 50 employees.